Jefferies Group restated their buy rating on shares of China Biologic Products (NASDAQ:CBPO) in a report released on Thursday morning. Jefferies Group currently has a $97.00 price objective on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of China Biologic Products from a hold rating to a sell rating in a research note on Monday, January 29th. BidaskClub cut shares of China Biologic Products from a sell rating to a strong sell rating in a research note on Friday, February 2nd. Deutsche Bank set a $105.00 price target on shares of China Biologic Products and gave the stock a buy rating in a research note on Friday, March 2nd. Finally, TheStreet cut shares of China Biologic Products from a b- rating to a c+ rating in a research note on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $101.00.
CBPO stock opened at $83.00 on Thursday. China Biologic Products has a 52 week low of $71.85 and a 52 week high of $120.46. The company has a market cap of $2,750.04, a price-to-earnings ratio of 34.73, a price-to-earnings-growth ratio of 1.18 and a beta of 1.62.
China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.01. China Biologic Products had a net margin of 18.34% and a return on equity of 21.30%. The business had revenue of $90.10 million during the quarter, compared to analysts’ expectations of $85.15 million. During the same period last year, the company posted $0.95 EPS. The business’s revenue was up 16.1% on a year-over-year basis. analysts anticipate that China Biologic Products will post 5.09 EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in CBPO. Vanguard Group Inc. boosted its stake in shares of China Biologic Products by 424.4% during the 2nd quarter. Vanguard Group Inc. now owns 23,686 shares of the biopharmaceutical company’s stock worth $2,679,000 after purchasing an additional 19,169 shares during the period. First Trust Advisors LP lifted its holdings in China Biologic Products by 16.3% during the 3rd quarter. First Trust Advisors LP now owns 18,814 shares of the biopharmaceutical company’s stock valued at $1,736,000 after buying an additional 2,641 shares in the last quarter. Sei Investments Co. bought a new stake in China Biologic Products during the 3rd quarter valued at about $3,223,000. Bank of New York Mellon Corp lifted its holdings in China Biologic Products by 30.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 762,784 shares of the biopharmaceutical company’s stock valued at $70,380,000 after buying an additional 176,325 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in China Biologic Products by 80.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 256,852 shares of the biopharmaceutical company’s stock valued at $23,700,000 after buying an additional 114,886 shares in the last quarter. 56.27% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “China Biologic Products (CBPO) Given “Buy” Rating at Jefferies Group” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/19/china-biologic-products-cbpo-given-buy-rating-at-jefferies-group.html.
About China Biologic Products
China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.